Back to Results

A PHASE 1/2, OPEN-LABEL, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY STUDY OF REPOTRECTINIB IN PEDIATRIC AND YOUNG ADULT SUBJECTS WITH ADVANCED OR METASTATIC MALIGNANCIES HARBORING ALK, ROS1, OR NTRK1-3 ALTERATIONS

Study

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Margaret Macy,  MD

Margaret Macy, MD

Study ID

Protocol Number: 19-2438

More information available at ClinicalTrials.gov: NCT04094610

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers